Singapore Hepatology Conference (SHC) 2019
Suntec Singapore International ConventionSingapore, SINGAPORE Visit the Venue to read more
After the fruitful SHC 2018, we can reflect back on a year of extraordinary advances in viral hepatitis. For HCV, the dream of short term pangenotypic therapy is getting closer. The all oral drug regimens are now becoming a reality even in Asia but there is still considerable uncertainty about which regimens to use and in which patients. The hard to treat genotype 3 is still challenging in some situations. For HBV, treatment options using interferon and nucleos(t)ide analogues are still being explored with interesting results, but the possibility of stopping therapy in some patients leading to HBsAg seroclearance seems quite astonishing. The most exciting developments are the new therapeutic agents in clinical trial (core inhibitor, TLR7 agonists, therapeutic vaccines, siRNA) that may lead to HBsAg seroclearance, now considered to be a functional cure of HBV.
With exciting internationally renowned speakers, and a very good clinically orientated programme together with case discussions, you will be completely updated on management of HCV, HBV and other liver diseases in 2 full days. I promise you, you won’t be disappointed!!
Warmest regards and welcome to Singapore in 2019!
Professor Seng Gee Lim
Singapore Hepatology Conference
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
JTB Pte Ltd – Event Support and Travel Management
79 Anson Road, #07—04, Singapore 079906
Tel: +65 6595 9919
Please contact the Official Travel Agent if you wish to book at one of the SHC 2019’s Official Hotels.
Singapore Hepatitis Conference Pte Ltd
20 Maxwell Road
#09-17 Maxwell House
Tel: +65 8620 3404